ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1867

Investigating Adenosine Deaminase 2 Activity in Large Vessel Vasculitis

Andrew Porter1, Robert Maughan1, Charis Pericleous1, Allan Kiprianos1, Hyuk Jee2, Pui Lee2, Taryn Youngstein1 and Justin Mason1, 1Imperial College London, London, United Kingdom, 2Boston Children's Hospital, Newton, MA

Meeting: ACR Convergence 2021

Keywords: giant cell arteritis, Takayasu.s arteritis, Vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) leads to a broad phenotype that in some resembles polyarteritis nodosa with fever and rash, but in others is characterised by stroke or immunodeficiency. Small, medium and large vessel vasculitis has been reported. In contrast, plasma ADA2 activity is elevated in inflammatory conditions including systemic lupus erythematosus and systemic juvenile idiopathic arthritis with macrophage activation syndrome. The role of ADA2 and how its deficiency associates with the vasculitides is not yet understood. Using a well-characterised large vessel vasculitis cohort we sought to establish the potential role of ADA2 activity.

Methods: ADA2 activity was measured in adults with Takayasu arteritis (TA), large vessel giant cell arteritis (LV-GCA), intracranial vasculitis (IV) and healthy control (HC) subjects (Table 1), using a coupled spectrophotometric assay as previously described. Plasma from 11 patients with genotyped DADA2 and 10 patients heterozygous for pathogenic variants in ADA2 were used to define thresholds for deficiency and carrier status respectively (DADA2 activity 0 – 0.90 U/L, ADA2 carrier activity 2.02 – 10.62 U/L). Activity levels above the upper limit of normal (ULN) were defined as >99th percentile of the HC activity (30.3 U/L). To assess potential associations with TA disease status, ADA2 was measured prospectively in matched active and remission samples.

TA disease activity was determined as active, grumbling or stable using clinical and radiological features, physician impression, CRP, ESR and Indian Takayasu clinical Activity Score (ITAS).

Median values are presented with differences between groups analysed using non-parametric tests, P< 0.05 was considered significant.

Results: No patients were found to have ADA2 deficiency while 7 subjects had activity within the carrier range (1 HC (1.9%), 5 TA (3.7%), 1 LV-GCA (2.3%)). Compared to HC levels (17.43 [14.11 – 20.78] U/L), activity in the TA group was significantly increased (TA 19.68U/L, p= 0.0061), while LV-GCA and IV were not significantly different (Figure 2). In 20 cases activity exceeded the upper limit of normal; 16 TA (11.9%, p=0.044; 4 active, 2 grumbling, 10 stable) and 4 LV-GCA (9.1%, ns). In TA, there was a positive correlation between ADA2 activity and ESR (Spearman R = 0.2863, p=0.0009) but not with CRP or ITAS score.

Subgroup analysis revealed that ADA2 activity was most prominently elevated in the stable group relative to HCs (TA stable 20.54 U/L [8.08 – 48.66], median +17.8%, p= 0.0006), but not with active or grumbling disease. Consistent with this, prospective analysis demonstrated a significant increase in ADA2 activity in remission vs active disease (p=0.024), with activity increasing in 18 (62%) patients achieving remission (Figure 3).

Conclusion: There were no cases of ADA2 deficiency in this cohort. Consistent with other inflammatory conditions, ADA2 activity was elevated in TA compared to HC subjects. Surprisingly, increased ADA2 activity was linked to stable TA in both cross-sectional and prospective analyses. This may suggest a potential role of ADA2 enzyme activity in vascular repair and regrowth – possibly tying in with known elevated levels of ADA2 activity in growing children

Table 1 – Demographic data. LV-GCA – large vessel giant cell arteritis. ITAS – Indian Takayasu clinical Activity Score. ESR – Erythrocyte sedimentation rate. CRP – C-reactive protein.

Figure 2 – ADA2 activity in groups. Upper limit normal – defined as >99% percentile of HC activity (30.3U/L). Upper and lower carrier level (2.02_10.62U/L) – determined from 10 patients heterozygous for pathogenic variants in ADA2. ** p < 0.01

Figure 3 – ADA2 activity in prospective active and remission samples. Increased – ADA2 activity higher in remission vs active. Decreased – ADA2 activity lower in remission vs active.


Disclosures: A. Porter, None; R. Maughan, None; C. Pericleous, None; A. Kiprianos, None; H. Jee, None; P. Lee, None; T. Youngstein, None; J. Mason, None.

To cite this abstract in AMA style:

Porter A, Maughan R, Pericleous C, Kiprianos A, Jee H, Lee P, Youngstein T, Mason J. Investigating Adenosine Deaminase 2 Activity in Large Vessel Vasculitis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/investigating-adenosine-deaminase-2-activity-in-large-vessel-vasculitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/investigating-adenosine-deaminase-2-activity-in-large-vessel-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology